权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Smart polymer for antibody purification

用于抗体纯化的智能聚合物

基本信息

批准号：
493244-2015
负责人：
Gauthier, Marc
金额：
$ 2.91万
依托单位：
Institut national de la recherche scientifique
依托单位国家：
加拿大
项目类别：
Collaborative Research and Development Grants
财政年份：
2016
资助国家：
加拿大
起止时间：
2016-01-01 至 2017-12-31
项目状态：
已结题

来源：
https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=602497
关键词：
Smart polymer antibody purification

项目摘要

Therapeutic strategies involving human monoclonal antibodies are becoming increasingly prevalent. Thus, the desire to reduce the cost of these drugs is exerting considerable pressure to make the manufacturing process more efficient and cost effective. However, while cell-culturing technology to produce antibodies has improved to deliver yields greater than 5 g/L, purification of the antibody from the medium has become a major process bottleneck. Currently, the use of chromatography columns that selectively capture antibodies from cell culture medium is the most effective method for purifying antibodies. Unfortunately, existing columns are extremely expensive, require harsh cleaning/regeneration processes in order to be reused, and often bind the target in a less-than-stoichiometric amount due to its immobilization on a solid support. To address these shortcomings, BioAstra Technologies Inc. and INRS will develop a recyclable scavenger that can capture and retrieve monoclonal antibodies from cell culture medium, thereby bypassing the need for chromatography. This project represents an excellent opportunity to train HQP in this area, which is of great social and economic importance. The output of this project will constitute a major technological advance that will reduce the cost of monoclonal antibodies and their corresponding therapies.

涉及人单克隆抗体的治疗策略正变得越来越普遍。因此，降低这些药物成本的愿望正在施加相当大的压力，以使制造过程更有效且更具成本效益。然而，虽然生产抗体的细胞培养技术已经改进以提供大于5g/L的产率，但从培养基中纯化抗体已经成为主要的工艺瓶颈。目前，使用从细胞培养基中选择性捕获抗体的层析柱是纯化抗体的最有效方法。不幸的是，现有的柱非常昂贵，需要苛刻的清洁/再生过程以便重复使用，并且由于其固定在固体载体上，通常以小于化学计量的量结合靶。为了解决这些缺点，BioAstra Technologies Inc. INRS将开发一种可回收的清除剂，可以从细胞培养基中捕获和回收单克隆抗体，从而绕过色谱法的需要。该项目是在这一领域培训HQP的绝佳机会，这具有重要的社会和经济意义。该项目的产出将构成一项重大的技术进步，将降低单克隆抗体及其相应疗法的成本。